Systematic Literature Review of the Economic Burden of Celiac Disease

Elizabeth S. Mearns (), Aliki Taylor, Talia Boulanger, Kelly J. Craig, Michele Gerber, Daniel A. Leffler, Jennifer Drahos, David S. Sanders and Benjamin Lebwohl
Additional contact information
Elizabeth S. Mearns: ZS Associates
Aliki Taylor: Takeda Development Centre Europe
Kelly J. Craig: Truven Health Analytics, An IBM Company
Michele Gerber: Takeda Pharmaceuticals International Co
Daniel A. Leffler: Takeda Pharmaceuticals International Co
Jennifer Drahos: Takeda Pharmaceuticals International Co
David S. Sanders: Royal Hallamshire Hospital and University of Sheffield
Benjamin Lebwohl: Celiac Disease Center, Columbia University Medical Center

PharmacoEconomics, 2019, vol. 37, issue 1, No 5, 45-61

Abstract: Abstract Background The prevalence of celiac disease (CD) has rapidly increased over recent decades, but costs related to CD remain poorly quantified. Objective This systematic review assessed the economic burden of CD in North America and Europe. Methods MEDLINE, EMBASE, EconLit, and the Cochrane Library databases were systematically searched to identify English-language literature from 2007 to 2018 that assessed costs, cost effectiveness, and health resource utilization for CD. Results Forty-nine studies met the inclusion criteria, of which 28 (57.1%) addressed costs of testing and diagnosis; 33 (67.3%) were from Europe. The cost per positive CD diagnosis of testing patients already undergoing esophagogastroduodenoscopy for other indications ranged from 1300 Canadian dollars ($Can) in Canada (2016 value) to €44,712 in the Netherlands (2013 value). Adding the CD test was cost effective when it combined diagnostic modalities (e.g., serology and biopsy). Direct annual excess costs to a US payer per diagnosed CD patient totaled $US6000 (2013 value) more than for a person without CD, chiefly due to outpatient care. Hospitalizations, emergency visits, and medication use were more common with CD. After initiating a gluten-free diet (GFD), patients visited primary care providers less often, used more medications, and missed fewer days from school and work. Conclusions Most of the few available economic studies of CD assess testing and diagnosis costs, especially in Europe. Methods of testing generally are considered cost effective when they combine diagnostic modalities in symptomatic patients. Most costs to a payer of managing CD derive from outpatient care. Following GFD initiation, patients lose fewer days from work and school than pretreatment.

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-018-0707-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:37:y:2019:i:1:d:10.1007_s40273-018-0707-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-018-0707-5

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().